Dharmpal S Dodd

USPTO Granted Patents = 43 (Patent Applications = 4)

CIPO Patents = 2 (Patent Applications = 9)

EPO Patents = 26 (Patent Applications = 26)

Average Co-Inventor Count = 7.1

ph-index = 6

Forward Citations = 145(Granted Patents)

Location History:

San Diego, CA (US) (2023)
Princeton, NJ (US) (2006 - 2024)
Monmouth Junction, NJ (US) (2019 - 2024)

Company Filing History:

43 out of 3,681

Bristol-myers Squibb Compnay

where one patent can have more than one assignee

Years Active: 2006-2025

Loading Chart...

43 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12404239 - Modulators of BCL6 as ligand directed degraders (2025-09-02),

2. 12384760 - Substituted carbazole compounds (2025-08-12),

3. 12030878 - Substituted indole ether compounds (2024-07-09),

4. RE49931 - [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds (2024-04-23),

5. RE49893 - [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds (2024-04-02),

6. RE49880 - [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds (2024-03-26),

7. 11912703 - 6-azaindole compounds (2024-02-27),

8. 11878975 - Substituted indole compounds useful as TLR inhibitors (2024-01-23),

9. 11820768 - 4-azaindole compounds (2023-11-21),

10. 11739098 - Substituted indole compounds (2023-08-29),

11. 11672780 - [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds (2023-06-13),

12. 11660311 - Cyclic dinucleotides as anticancer agents (2023-05-30),

13. 11447466 - Substituted indole compounds useful as inhibitors of TLR7/8/9 (2022-09-20),

14. 11427580 - 6-azaindole compounds (2022-08-30),

15. 11420973 - Amide substituted indole compounds useful as TLR inhibitors (2022-08-23),

Title: Innovation and Impact: The Contributions of Dharmpal S Dodd

Introduction

Dharmpal S Dodd, based in Princeton, NJ, has made significant strides in the field of pharmaceuticals with an impressive portfolio of 41 patents. His groundbreaking work focuses primarily on compounds useful in treating inflammatory and autoimmune diseases, showcasing his commitment to innovative healthcare solutions.

Latest Patents

Among his latest inventions are the following patents:

1. **Substituted Indole Ether Compounds** - This patent discloses compounds of Formula (I) N-oxides, or salts thereof, wherein specific variables are defined. The compounds are described as inhibitors of signaling through Toll-like receptors 7, 8, or 9, and offer potential therapeutic applications in treating inflammatory and autoimmune diseases.

2. **Triazolo[1,5-a]pyridinyl Substituted Indole Compounds** - This patent reveals compounds of Formula (I) or a salt thereof, with defined variables. Similarly, these compounds serve as inhibitors for signaling through Toll-like receptors 7, 8, or 9 and also provide insights into pharmaceutical compositions aimed at combating inflammatory and autoimmune diseases.

Career Highlights

Dharmpal's extensive career includes distinguished roles at reputable organizations, such as Bristol-Myers Squibb Company and Cerep SA. These experiences have played a crucial role in shaping his expertise and contributions in the pharmaceutical field.

Collaborations

In the course of his career, Dharmpal has collaborated with notable professionals, including Christopher P Mussari and Alaric J Dyckman. Their collective efforts have undoubtedly enriched the innovative landscape in which they operate.

Conclusion

Dharmpal S Dodd stands out as an influential inventor whose work significantly contributes to the pharmaceutical industry. His dedication to developing novel compounds offers promising avenues for treating serious health conditions, underscoring the importance of innovation in advancing medical science.

This text is generated by artificial intelligence and may not be accurate.